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necessarily mean there is only one
candidate gene. We do not know
whether SSH1, ARPC3, and SART3 are
involved in the same pathway, but
some papers suggest that SSH1 and
ARPC3 may be involved in the actin
cytoskeleton pathway (Welch et al.,
1997; Pollard et al., 2000; Volkmann
et al., 2001; Niwa et al., 2002; Pelham
and Chang, 2002).
As to the heterozygous C/A-peak
perhaps it is caused by the low-resolu-
tion online image referred to (Figure 1
which is reproduced here). We are not
sure whether the S63N mutation is
innocuous or not, but it should be
confirmed by experiments.
We sincerely thank the authors for
their attention to our research. The
conclusions in our papers may be not
perfect, but the data generated by the
experiment are valid.
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TO THE EDITOR
An Associate Editor with expertise in
the field reviewed the online publica-
tion in question, along with an inde-
pendent observer, and agrees with Dr
Zhang. In addition, the Editor reviewed
all figures associated with this publica-
tion, including those submitted for
review purposes and those published
online and in print, and the Editor
agrees with Dr Zhang. The Editor
appreciates the concern over the valid-
ity of original data published in the JID,
and considers this case closed.
Lowell A. Goldsmith
Editor
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TO THE EDITOR
Pachyonychia congenita is a rare
autosomal-dominant disorder of keratin
that was first described in 1685 (Leach-
man et al., 2005). Named by Jadassohn
and Lewandowsky in 1906, this syn-
drome is characterized by hypertrophic
nail dystrophy, focal palmoplantar
keratoderma, follicular keratoses, and
other ectodermal features varying
by subtype. It is now well known that
pachyonychia congenita type 1 (PC-1),
also known as Jadassohn–Lewandowsky
syndrome, is caused by mutations in
either keratin 6a (K6a) or keratin 16
(K16), whereas pachyonychia con-
genita type 2 (PC-2), also known as
Jackson–Lawler syndrome, is caused
by mutations in keratin 6b (K6b) or
its expression partner keratin 17 (K17)
(Munro, 2001). Both subtypes have
hypertrophic nail dystrophy and painful
plantar keratoderma as the most
significant clinical findings with fea-
tures such as natal teeth, steatocysts,
and hair abnormalities being more
common in PC-2 and oral leukokera-
tosis more common in pachyonychia
congenita type 1 (Leachman et al.,
2005).
The number of patients worldwide
that are believed to have PC is between
1,000 and 10,000 (Kaspar, 2005). There
have been more than 82 mutations
published in the literature thus far with
all established mutations consistent
Abbreviations: K6a, keratin 6a; K6b, keratin 6b; K16, keratin 16; K17, keratin 17; PC-1, pachyonychia
congenita type 1; PC-2, pachyonychia congenita type 2
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with an autosomal-dominant presenta-
tion or a spontaneous mutation (29–
46% of patients have a negative family
history) (Leachman et al., 2005). Nearly
all of the reported mutations occur at
the beginning or end of the central
keratin rod domain, within the helix
initiation motif or helix termination
motif (Smith et al., 2005). These parti-
cular regions are integral in end-to-end
association of protein subunits during
keratin filament assembly (Smith et al.,
2005). In PC-2, mutations have been
noted in the helix initiation and termi-
nation motifs of K17, but only in the
helix termination motif of K6b (Smith
et al., 1998; Leachman et al., 2005).
We report a patient with typical clinical
features of PC-2 and a novel mutation
in the helix initiation motif of K6b, the
first genetic defect identified in this
portion of the gene.
A 14-year-old Caucasian female
presented to our university clinic in
January 2000. She reported history of
thickened nails since she was 2 months
old and thickening of her soles over the
past several years. However, she was
most bothered by the continued develop-
ment of multiple cysts, clinically con-
sistent with steatocystomas and milia.
On physical exam, she had thick,
hyperkeratotic toenails and yellowish,
hyperkeratotic plaques on bilateral soles
(Figure 1). She had multiple milia and
steatocystomas scattered over her face
and upper chest (Figure 2). She had no
oral lesions, and her hair and teeth were
normal. There was no definite family
history, but her father reportedly had
dystrophic toenails (evaluation and ge-
netic testing of the parents were refused).
After obtaining informed consent,
and in compliance with the Declaration
of Helsinki Principles, genomic DNA
was extracted from a buccal swab
obtained from the patient by standard
method. Direct sequencing of DNA
from the patient revealed a heterozy-
gous deletion of three base pairs in
exon 1 of the KRT6B gene, in the helix
initiation motif. The mutation is de-
noted p.Asn172del (N172del) on the
protein level and c.516_518del3 on the
cDNA level. No mutations were found
in the keratin 6a, keratin 16, or K17
genes. The K6b mutation identified in
this patient has not previously been
reported. Interestingly, the analogous
amino acid on keratin 6a has been
found to contain deletions or missense
mutations resulting in clinical features
consistent with PC-1. Moreover, N172
(or N171 depending on the numbering
convention used) on keratin 6a is the
most common locus for mutation in
PC-1 (Leachman et al., 2005; Smith
et al., 2005).
Although other mutations in K6b
have been reported, this is the first
mutation to be found within the helix
initiation motif of K6b. Other known
mutations in PC-2 include a heterozy-
gous missense mutation E472K, located
in the helix termination motif of K6b,
and a handful of mutation sites in the
helix initiation and termination motifs
of K17 (Covello et al., 1998; Smith
et al., 1998; Hashiguchi et al., 2002;
Smith et al., 2005; Oh et al., 2006).
Keratins are structural proteins that
form heterodimeric filaments, ex-
pressed in epithelial tissues as specific
type I and type II keratin pairs (Smith
et al., 2005). In PC-2, the defective
keratins are either K17 or K6b, which
are constitutively expressed in the
luminal cell layers of sebaceous glands,
matrix and outer root sheath of hair
follicles, and in the nail bed. Defects in
these genes are thought to lead to
keratinocyte fragility, leading to the
clinical phenotype of PC-2 (Smith
et al., 2005). Significant overlap
has been noted in patients with PC-2
and steatocystoma multiplex. The K17
mutation at R94C has been shown to
cause steatocystoma multiplex without
the nail changes in some families and
the full PC-2 clinical phenotype in
others, leading to the hypothesis that
genetic or environmental modifiers
a b
Figure 1. Clinical features of the patient with K6b mutation. (a) Photograph of the hyperkeratotic,
dystrophic toenails. (b) Plantar keratoderma with fissuring and scale.
Figure 2. Facial steatocystomas. Note the multiple skin-colored papules on the patient’s face with two
papules extruding greasy contents consistent with steatocystomas.
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influence the genotype–phenotype re-
lationship (Covello et al., 1998; Leach-
man et al., 2005). No patients have
been reported with K6b mutations and
pure steatocystoma multiplex (McLean
et al., 2005), but our patient does have
multiple flesh-colored papules which
extrude greasy contents, consistent with
steatocystomas.
Treatment for pachyonychia conge-
nita is limited and fairly unsuccessful by
current standards. The most debilitating
feature as reported by patients is plantar
pain, with the most promising treat-
ments thus far consisting of activities to
reduce friction and botulinum toxin to
decrease sweating (Leachman et al.,
2005; Milstone et al., 2005). Other
features, such as hyperkeratosis of the
nails, cysts, and mucous membrane
lesions are managed by symptomatic
treatment ranging from use of humec-
tants and mechanical removal of kera-
tin in thick nails to excision or incision
and drainage of cysts. Fortunately,
newer and better gene-based treatments
are on the horizon. Exciting options
being considered include triplex-form-
ing oligonucleotides or zinc-finger
nucleases to inactivate or induce
correction of the mutant allele and
most promising to date, the use of
targeted small inhibitory RNAs to si-
lence gene expression of the mutant
allele (Lewin et al., 2005; Hickerson
et al., 2006). Hopefully, with continued
research into the genetics of pachyo-
nychia congenita, the goal of gene-
based therapy will become attainable.
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P75 Plays a Key Role in the Induction of the Sprouting of
Sensory Nerve Fibers in Inflamed Skin
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TO THE EDITOR
In hyperkeratosis and acanthosis, periph-
eral branches of sensory nerves increase
remarkably in number, particularly in the
epidermis of inflamed skin (Mihm et al.,
1976; Pincelli et al., 1990; Tobin et al.,
1992; Ostlere et al., 1995). It has been
supposed that nerve growth factor (NGF)
secreted from keratinocytes in inflamed
skin may induce the sprouting of the
neurites of sensory fibers (Dou et al.,
2006) because of an increase in both
NGF expression in the keratinocytes
(Kinkelin et al., 2000; Takano et al.,
2005; Tanaka and Matsuda, 2005) and
cutaneous innervation in the epidermis
in the inflamed skin (Horiuchi et al.,
2005). The NGF effect may occur
via low-affinity receptors (p75) and
high-affinity receptors (TrkA), although
direct evidence for this is lacking.
This study clearly demonstrates, by
using p75 knockout mice, that sprout-
ing of sensory fibers in the epidermis
and hyperkeratosis and acanthosis of
the inflamed skin are induced by an
NGF–p75 pathway.Abbreviations: NGF, nerve growth factor; PC, picryl chloride (2,4,6-trinitrochlorobenzene)
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